Ident. | Authors (with country if any) | Title |
---|
000278 |
K. Dujardin [France] ; N. Auzou [France] ; E. Lhommée [France] ; V. Czernecki [France] ; B. Dubois [France] ; A. Fradet [France] ; D. Maltete [France] ; M. Meyer [France] ; F. Pineau [France] ; E. Schmitt [France] ; F. Sellal [France] ; F. Tison [France] ; T. Vidal [France] ; J-P Azulay [France] ; M-L Welter [France] ; J-C Corvol [France] ; F. Durif [France] ; O. Rascol [France] | French consensus procedure for assessing cognitive function in Parkinson's disease. |
000590 |
K Ray Chaudhuri [Royaume-Uni] ; A. Rizos [Royaume-Uni] ; C. Trenkwalder [Allemagne] ; O. Rascol [France] ; S. Pal [Royaume-Uni] ; D. Martino [Royaume-Uni] ; C. Carroll [Royaume-Uni] ; D. Paviour [Royaume-Uni] ; C. Falup-Pecurariu [Roumanie] ; B. Kessel [Royaume-Uni] ; M. Silverdale [Royaume-Uni] ; A. Todorova [Royaume-Uni] ; A. Sauerbier [Royaume-Uni] ; P. Odin [Suède] ; A. Antonini [Italie] ; P. Martinez-Martin [Espagne] | King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. |
000647 |
A. Antonini [Italie] ; L. Bauer [Allemagne] ; E. Dohin [France] ; W H Oertel [Allemagne] ; O. Rascol [France] ; H. Reichmann [Allemagne] ; M. Schmid [Allemagne] ; P. Singh [Allemagne] ; E. Tolosa [Espagne] ; K Ray Chaudhuri [Royaume-Uni] | Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. |
000682 |
P. Odin [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] ; J T Slevin [États-Unis] ; J. Volkmann [Allemagne] ; E. Dietrichs [Norvège] ; P. Martinez-Martin [Espagne] ; J K Krauss [Allemagne] ; T. Henriksen [Danemark] ; R. Katzenschlager [Autriche] ; A. Antonini [Italie] ; O. Rascol [France] ; Werner Poewe [Autriche] | Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. |
000D32 |
P. Péran [France] ; F. Nemmi ; D. Méligne ; D. Cardebat ; A. Peppe ; O. Rascol ; C. Caltagirone ; J F Demonet ; U. Sabatini | Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study. |
000D94 |
Stephan Klebe [France, Allemagne] ; Jean-Louis Golmard [France] ; Michael A. Nalls [États-Unis] ; Mohamad Saad [France] ; Andrew B. Singleton [États-Unis] ; Jose M. Bras [Royaume-Uni] ; John Hardy [Royaume-Uni] ; Javier Simon-Sanchez [États-Unis, Pays-Bas] ; Peter Heutink [Pays-Bas] ; Gregor Kuhlenb Umer [Allemagne] ; Rim Charfi [France, Tunisie] ; Christine Klein [Allemagne] ; Johann Hagenah [Allemagne] ; Thomas Gasser [Allemagne] ; Isabel Wurster [Allemagne] ; Suzanne Lesage [France] ; Delia Lorenz [Allemagne] ; Günther Deuschl [Allemagne] ; Franck Durif [France] ; Pierre Pollak [France] ; Philippe Damier [France] ; François Tison [France] ; Alexandra Durr [France] ; Philippe Amouyel [France] ; Jean-Charles Lambert [France] ; Christophe Tzourio [France] ; Cécilia Maubaret [France] ; Fanny Charbonnier-Beaupel [France] ; Khadija Tahiri [France] ; Marie Vidailhet [France] ; Maria Martinez [France] ; Alexis Brice [France] ; Jean-Christophe Corvol [France] ; Yves Agid [France] ; M. Anheim ; A-M Bonnet ; M. Borg ; A. Brice ; E. Broussolle ; J-C Corvol ; Ph. Damier ; A. Destée ; A. Durr ; F. Durif ; S. Klebe ; E. Lohmann ; M. Martinez ; C. Penet ; P. Pollak ; P. Krack ; O. Rascol ; F. Tison ; C. Tranchant ; M. Vérin ; F. Viallet ; Vincent Plagnol ; Jose M. Bras ; Dena G. Hernandez ; Manu Sharma ; Una-Marie Sheerin ; Mohamad Saad ; Javier Sim N-Sánchez ; Claudia Schulte ; Suzanne Lesage ; Sigurlaug Sveinbjörnsd Ttir ; Philippe Amouyel ; Sampath Arepalli ; Gavin Band ; Roger A. Barker ; Céline Bellinguez ; Yoav Ben-Shlomo ; Henk W. Berendse ; Daniela Berg ; Kailash Bhatia ; Rob Ma De Bie ; Alessandro Biffi ; Bas Bloem ; Zoltan Bochdanovits ; Michael Bonin ; Kathrin Brockmann ; Janet Brooks ; David J. Burn ; Gavin Charlesworth ; Honglei Chen ; Patrick F. Chinnery ; Sean Chong ; Carl E. Clarke ; Mark R. Cookson ; J Mark Cooper ; Jean Christophe Corvol ; Carl Counsell ; Philippe Damier ; Jean-François Dartigues ; Panos Deloukas ; David T. Dexter ; Karin D. Van Dijk ; Allissa Dillman ; Frank Durif ; Sarah Edkins ; Jonathan R. Evans ; Thomas Foltynie ; Colin Freeman ; Jianjun Gao ; Michelle Gardner ; Raphael Gibbs ; Alison Goate ; Emma Gray ; Rita Guerreiro ; Mar Gústafsson ; Clare Harris ; Garrett Hellenthal ; Jacobus J. Van Hilten ; Albert Hofman ; Albert Hollenbeck ; Janice Holton ; Michele Hu ; Xuemei Huang ; Heiko Huber ; Gavin Hudson ; Sarah E. Hunt ; Johanna Huttenlocher ; Thomas Illig ; Pálmi V. J Nsson ; Cordelia Langford ; Andrew Lees ; Peter Lichtner ; Patricia Limousin ; Grisel Lopez ; Delia Lorenz ; Alisdair Mcneill ; Catriona Moorby ; Huw Morris ; Karen E. Morrison ; Ese Mudanohwo ; Sean S. O'Sullivan ; Justin Pearson ; Richard Pearson ; Joel S. Perlmutter ; Hjörvar Pétursson ; Matti Pirinen ; Pierre Pollak ; Bart Post ; Simon Potter ; Bernard Ravina ; Tamas Revesz ; Olaf Riess ; Fernando Rivadeneira ; Patrizia Rizzu ; Mina Ryten ; Stephen Sawcer ; Anthony Schapira ; Hans Scheffer ; Karen Shaw ; Ira Shoulson ; Ellen Sidransky ; Rohan De Silva ; Colin Smith ; Chris Ca Spencer ; Hreinn Stefánsson ; Stacy Steinberg ; Joanna D. Stockton ; Amy Strange ; Zhan Su ; Kevin Talbot ; Carlie M. Tanner ; Avazeh Tashakkori-Ghanbaria ; François Tison ; Daniah Trabzuni ; Bryan J. Traynor ; G. Uitterlinden ; Jana Vandrovcova ; Daan Velseboer ; Marie Vidailhet ; Damjan Vukcevic ; Robert Walker ; Bart Van De Warrenburg ; Michael E. Weale ; Mirdhu Wickremaratchi ; Nigel Williams ; Caroline H. Williams-Gray ; Sophie Winder-Rhodes ; Maria Martinez ; Peter Donnelly ; John Hardy ; Peter Heutink ; Alexis Brice ; Thomas Gasser ; Nicholas W. Wood ; Andrew B. Singleton | The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism |
000E24 |
J. J. Ferreira [Portugal] ; R. Katzenschlager [Autriche] ; B. R. Bloem [Pays-Bas] ; U. Bonuccelli [Italie] ; D. Burn [Royaume-Uni] ; G. Deuschl [Allemagne] ; E. Dietrichs [Norvège] ; G. Fabbrini [Italie] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; V. Kostic [Serbie] ; A. Nieuwboer [Belgique] ; P. Odin [Allemagne, Suède] ; Werner Poewe [Autriche] ; O. Rascol [France] ; C. Sampaio [Portugal] ; M. Schüpbach [France, Suisse] ; E. Tolosa [Espagne] ; C. Trenkwalder [Allemagne] ; A. Schapira [Royaume-Uni] ; A. Berardelli [Italie] ; W. H. Oertel [Allemagne] | Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease |
000E25 |
A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; C. Debieuvre [France] ; M. Fraessdorf [Allemagne] ; Werner Poewe [Autriche] | Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's disease |
000E44 |
A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; C. Debieuvre [France] ; M. Fraessdorf [Allemagne] ; Werner Poewe [Autriche] | Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease |
000F76 |
P. Peran [France, Italie] ; F. Nemmi [Italie] ; D. Meligne [France] ; D. Cardebat [France] ; A. Peppe [Italie] ; O. Rascol [France] ; C. Caltagirone [Italie] ; J. F. Demonet [Suisse] ; U. Sabatini [Italie] | Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: A fMRI study |
001089 |
O. Rascol [France] ; J. Bronzova ; R A Hauser ; A E Lang ; C. Sampaio ; A. Theeuwes ; S V Van De Witte | Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. |
001245 |
S. Perez-Lloret [France, Argentine] ; L. Nègre-Pagès [France] ; A. Ojero-Senard [France] ; P. Damier ; A. Destée ; F. Tison [France] ; M. Merello [Argentine] ; O. Rascol [France] | Oro‐buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort |
001723 |
O. Rascol [France] | Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release |
001838 |
Werner Poewe [Autriche] ; O. Rascol [France] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno ; M. Haaksma ; L. Salin ; N. Juhel ; A. H. V. Schapira | Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial |
001839 |
A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; L. Salin [France] ; N. Juhel [France] ; Werner Poewe [Autriche] | Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial |
001A08 |
P. Payoux [France] ; C. Brefel-Courbon ; F. Ory-Magne ; W. Regragui ; C. Thalamas ; S. Balduyck ; F. Durif ; J P Azulay ; F. Tison ; O. Blin ; J P Esquerre ; O. Rascol | Motor activation in multiple system atrophy and Parkinson disease: a PET study. |
001D31 |
P. Payoux [France] ; C. Brefel-Courbon [France] ; F. Ory-Magne [France] ; W. Regragui [France] ; C. Thalamas [France] ; S. Balduyck [France] ; F. Durif [France] ; J. P. Azulay [France] ; F. Tison [France] ; O. Blin [France] ; J. P. Esquerre [France] ; O. Rascol [France] | Motor activation in multiple system atrophy and Parkinson disease: A PET study |
002045 |
A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; O. Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne] | Perspectives on recent advances in the understanding and treatment of Parkinson’s disease |
002363 |
J. C. Sharma [Royaume-Uni] ; I. N. Ross [Royaume-Uni] ; O. Rascol [France] ; D. Brooks [Royaume-Uni] | Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight |
002443 |
O. Rascol [France] | Thérapeutiques du stade précoce de la maladie de Parkinson |
002698 |
A. Gerdelat-Mas [France] ; M. Simonetta-Moreau [France] ; C. Thalamas [France] ; F. Ory-Magne [France] ; T. Slaoui [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study |
002776 |
T. Slaoui [France] ; A. Mas-Gerdelat [France] ; F. Ory-Magne [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | La lévodopa modifie les seuils nociceptifs chez le patient parkinsonien |
002958 |
J. J. Ferreira [Portugal] ; K. Desboeuf [France] ; M. Galitzky [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; N. Fabre [France] ; J. Senard [France] ; J. Montastruc [France] ; C. Sampaio [Portugal] ; O. Rascol [France] | Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson's disease: a clinical survey in PD patients and age‐matched healthy volunteers |
002964 |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; O. Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease |
002D45 |
Carl E. Clarke [Royaume-Uni] ; O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. Melamed [Israël] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] ; E. Tolosa [Espagne] | Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary |
002F29 |
P. Pollak [France] ; F. Tison [France] ; O. Rascol [France] ; A. Destée [France] ; J J Péré [France] ; J M Senard [France] ; F. Durif [France] ; I. Bourdeix [France] | Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up |
003081 |
P. Cintas [France] ; M. Simonetta-Moreau ; F. Ory ; C. Brefel-Courbon ; N. Fabre ; P. Chaynes ; J. Sabatier ; J C Sol ; O. Rascol ; I. Berry ; Y. Lazorthes | Deep brain stimulation for parkinson's disease: correlation between intraoperative subthalamic nucleus neurophysiology and most effective contacts. |
003305 |
O. Rascol [France] ; J J Ferreira ; P. Payoux ; Ch Brefel-Courbon ; J L Montastruc | [Management of levodopa-induced dyskinesia]. |
003311 |
M. Simonetta Moreau [France] ; S. Meunier ; M. Vidailhet ; S. Pol ; M. Galitzky ; O. Rascol | Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease. |
003313 |
O. Rascol [France] ; P. Payoux ; J. Ferreira ; C. Brefel-Courbon | The management of patients with early Parkinson's disease. |
003421 |
O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France] | Prise en charge des dyskinésies par la lévodopa |
003464 |
M. Simonetta Moreau [France] ; S. Meunier [France] ; M. Vidailhet [France] ; S. Pol [France] ; M. Galitzky [France] ; O. Rascol [France] | Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease |
003568 |
F. Chollet [France] ; I. Loubinoux ; J. Pariente ; C. Carel ; J F Albucher ; O. Rascol ; B. Guiraud-Chaumeil | [Pharmacologic modification of cerebral activity: value of functional neuroimaging]. |
003572 |
O. Rascol [France] ; N. Fabre ; C. Brefel-Courbon ; J L Montastruc | The pharmacologic treatment of gait ignition failure. |
003824 |
O. Rascol [France] ; J. G. Nutt [États-Unis] ; O. Blin [France] ; C. G. Goetz [États-Unis] ; J. M. Trugman [États-Unis] ; C. Soubrouillard [France] ; J. H. Carter [États-Unis] ; L. J. Currie [États-Unis] ; N. Fabre [France] ; C. Thalamas [France] ; W. J. Giardina [États-Unis] ; S. Wright [États-Unis] | Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease |
003828 |
O. Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France] | Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease |
003839 |
S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France] | Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease |
003864 |
O. Rascol [France] ; J L Montastruc | [Role of dopaminergic agonists]. |
003869 |
O. Rascol [France] | The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. |
003872 |
J J Ferreira [France] ; O. Rascol | Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. |
003895 |
Jj Ferreira [France, Portugal] ; M. Galitzky [France] ; Jl Montastruc [France] ; O. Rascol [France] | Sleep attacks and Parkinson's disease treatment |
003B28 |
O. Rascol [France] ; J.-L. Montastruc [France] | La place des agonistes dopaminergiques |
003B58 |
O. Rascol [France] | The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease |
003B73 |
O. Rascol [France] | Medical treatment of levodopa-induced dyskinesias |
003C16 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
003C55 |
O. Rascol [France] | Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? |
003C58 |
O. Rascol [France] ; C. Brefel-Courbon ; S. Descombes ; J L Montastruc | Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients. |
003C60 |
M B Delisle [France] ; J R Murrell ; R. Richardson ; J A Trofatter ; O. Rascol ; X. Soulages ; M. Mohr ; P. Calvas ; B. Ghetti | A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. |
003E73 |
O. Rascol [France] | Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques |
003F04 |
C. Thalamas [France] ; A. Taylor [Royaume-Uni] ; C. Brefel-Courbon [France] ; S. Eagle [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; O. Rascol [France] | Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease |
003F05 |
O. Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |
003F34 |
O. Rascol [France] ; O. Blin [France] ; C. Thalamas [France] ; S. Descombes [France] ; C. Soubrouillard [France] ; P. Azulay [France] ; N. Fabre [France] ; F. Viallet [France] ; K. Lafnitzegger [États-Unis] ; S. Wright [États-Unis] ; J. H. Carter [États-Unis] ; J. G. Nutt [États-Unis] | ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease |
003F35 |
H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of salivary secretion in Parkinson's disease |
004109 |
O. Rascol [France] ; C. Brefel-Courbon [France] ; O. Blin [France] | Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens |
004128 |
C. Brefel-Courbon [France] ; C. Thalamas [France] ; H. Peyro Saint Paul [France] ; J.-M. Senard [France] ; J.-L. Montastruc [France] ; O. Rascol [France] | α2-Adrenoceptor antagonists: A new approach to Parkinson's disease? |
004134 |
A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie] | The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease |
004137 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
004138 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
004157 |
J. L. Montastruc [France] ; M. Pelat [France] ; P. Verwaerde [France] ; C. Brefel-Courbon [France] ; M. A. Tran [France] ; O. Blin [France] ; O. Rascol [France] ; J. M. Senard [France] | Fluoxetine in orthostatic hypotension of Parkinson's disease : A clinical and experimental pilot study |
004161 |
C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France] | Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients |
004174 |
D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni] | A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease |
004365 |
J.-L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France] | Pharmacologie des médicaments antiparkinsoniens : bilan et perspectives : Maladie de Parkinson |
004366 |
N. Fabre [France] ; C. Brefel-Courbon [France] ; O. Rascol [France] | Parkinson « plus » : Mouvements anormaux |
004387 |
O. Rascol [France] ; N. Fabre [France] ; U. Sabatini [Italie] | Imagerie fonctionnelle |
004391 |
O. Rascol [France] ; N. Fabre [France] ; J.-L. Montastruc [France] | Fluctuations de la réponse à la L-dopa dans la maladie de Parkinson : Maladie de Parkinson - 2e partie |
004403 |
C. Soubrouillard [France] ; C. Lombardo [France] ; O. Rascol [France] ; B. Bruguerolle [France] ; O. Blin [France] | Agonistes dopaminergiques centraux D1 et traitement de la maladie de Parkinson |
004411 |
O. Rascol [France] ; U. Sabatini [Italie] ; N. Fabre [France] ; C. Brefel [France] ; I. Loubinoux [France] ; P. Celsis [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; F. Chollet [France] | The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients |
004420 |
J. M. Senard [France] ; S. Rai [France] ; M. Lapeyre-Mestre [France] ; C. Brefel [France] ; O. Rascol [France] ; A. Rascol [France] ; J. L. Montastruc [France] | Prevalence of orthostatic hypotension in Parkinson's disease |
004437 |
J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France] | Glutamate antagonists and Parkinson's disease : A review of clinical data |
004484 |
J L Montastruc [France] ; J M Senard ; O. Rascol ; A. Rascol | Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. |
004486 |
O. Rascol [France] ; A J Lees ; J M Senard ; Z. Pirtosek ; C. Brefel ; J L Montastruc ; D. Fuell | A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. |
004661 |
O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell | Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease |
004682 |
M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients |
004692 |
J L Montastruc [France] ; O. Rascol ; J M Senard ; G. Houin ; A. Rascol | Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? |
004699 |
J M Sénard [France] ; P. Verwaerde ; O. Rascol ; J L Montastruc | Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians. |
004900 |
O. Rascol [France] ; U. Sabatini ; N. Fabre [France] ; J. M. Senard [France] ; M. Simonetta-Moreau [France] ; J. L. Montrastruc [France] ; M. Clanet [France] ; A. Rascol [France] | Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease |
004912 |
M E Llau [France] ; L. Nguyen ; J M Senard ; O. Rascol ; J L Montastruc | [Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance]. |
004942 |
O. Blin [France] ; C. Desnuelle [France] ; O. Rascol [France] ; M. Borg [France] ; H. Peyro Saint Paul [France] ; J. P. Azulay [France] ; F. Billé [France] ; D. Figarella [France] ; F. Coulom [France] ; J. F. Pellissier [France] ; J. L. Montastruc [France] ; M. Chatel [France] ; G. Serratrice [France] | Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy |
004A02 |
O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J M Senard [France] ; J L Montastruc [France] ; P. Celsis [France] ; J P Marc-Vergnes [France] ; A. Rascol [France] | Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. |
004A26 |
Jl Montastruc [France] ; Me Llau [France] ; O. Rascol [France] ; Jm Senard [France] | Drug‐induced parkinsonism: a review |
004A44 |
J L Montastruc [France] ; O. Rascol [France] ; J M Senard [France] ; A. Rascol [France] | A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. |
004A78 |
O. Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. Rascol | Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease |
004A80 |
H. Bagheri [France] ; M. Berlan ; J. M. Senard ; O. Rascol ; J. L. Montastruc | Lacrimation in Parkinson's disease |
004A93 |
J.-F. Demonet [France] ; P. Celsis [France] ; A. Agniel [France] ; D. Cardebat [France] ; O. Rascol [France] ; J.-P. Marc-Vegnes [France] | Activation of regional cerebral blood flow by a memorization task in early Parkinson's disease patients and normal subjects |
004C26 |
J. M. Senard [France] ; O. Rascol [France] ; B. Chamontin [France] ; A. Rascol [France] ; J.-L. Montastruc [France] | Enregistrement ambulatoire de la pression artérielle dans l'hypotension orthostatique de la maladie de Parkinson |
004C51 |
J. M. Senard [France] ; O. Rascol [France] ; A. Rascol ; J. L. Montastruc [France] | Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension |
004C61 |
J. M. Senard [France] ; O. Rascol [France] ; G. Durrieu [France] ; M. A. Tran [France] ; M. Berlan [France] ; A. Rascol ; J. L. Montastruc | Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy |
004C65 |
J. L. Montastruc [France] ; O. Rascol ; J. M. Senard | Current status of dopamine agonists in Parkinson's disease management |
004C70 |
N. Fabre [France] ; J. L. Montastruc ; O. Rascol | Alopecia : an adverse effect of bromocriptine |
004E33 |
O. Rascol [France] ; U. Sabatini ; F. Chollet ; P. Celsis ; J.-L. Montastruc ; J.-P. Marc-Vergnes ; A. Rascol | Supplementary and primary sensory motor area activity in Parkinson's disease : regional cerebral blood flow changes during finger movements and effects of apomorphine |
004E38 |
A. Kastner [France] ; E. C. Hirsch ; O. Lejeune ; F. Javoy-Agid ; O. Rascol [France] ; Yves Agid [France] | Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content ? |
004F52 |
A. Agniel [France] ; P. Celsis [France] ; G. Viallard [France] ; J L Montastruc [France] ; O. Rascol [France] ; J F Demonet [France] ; J P Marc-Vergnes [France] ; A. Rascol [France] | Cognition and cerebral blood flow in lateralised parkinsonism: lack of functional lateral asymmetries. |
004F89 |
J. L. Montrastuc [France] ; O. Rascol ; J. M. Senard ; V. Gualano ; H. Bagheri ; G. Houin ; A. Lees ; A. Rascol | Sublingual apomorphine in Parkinson's disease : a clinical and pharmacokinetic study |
004F90 |
U. Sabatini [France] ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J. P. Marc-Vergnes ; J. L. Montastruc | Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms |
004F91 |
O. Rascol [France] ; U. Sabatini ; SIMONETTA-MOREAU ; J. L. Montastruc ; A. Rascol ; M. Clanet | Square wave jerks in Parkinsonian syndromes |
005011 |
G. Durrieu [France] ; J M Senard ; O. Rascol ; M A Tran ; X. Lataste ; A. Rascol ; J L Montastruc | Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243). |
005036 |
U. Sabatini [France] ; O. Rascol [France] ; P. Celsis [France] ; J. P. Marc-Vergnes [France] ; J. L. Montastruc [France] | Effects of apomorphine on cerebral blood flow and extrapyramidal symptoms in Parkinson's disease |
005117 |
J.-L. Montastruc [France] ; O. Rascol ; J.-M. Senard | Les médicaments anti-parkinsoniens : bilan et nouvelles perpectives pharmacologiques |
005156 |
M. Berlan [France] ; O. Rascol ; J. Belin ; J P Moatti ; A. Rascol ; J L Montastruc | Alpha 2-adrenergic sensitivity in Parkinson's disease. |
005219 |
J L Montastruc [France] ; O. Rascol [France] ; A. Rascol [France] | A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. |
005926 |
O. Rascol [France] ; C. Brefel-Courbon ; O. Blin | [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients]. |
005945 |
J L Montastruc [France] ; C. Brefel-Courbon ; J M Senard ; H. Bagheri ; J. Ferreira ; O. Rascol ; M. Lapeyre-Mestre | Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. |
005952 |
O. Rascol [France] ; D J Brooks ; E. Melamed ; W. Oertel ; Werner Poewe ; F. Stocchi ; E. Tolosa | Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. |